Drug Morepen Laboratories today said it has signed an agreement with Belgian firm Vesale Pharma to strengthen its presence in the probiotics segment.
The tie up will expand Morepen's formulations portfolio especially in the gastroenterology segment in the Indian market. Initially it is an exclusive distribution and marketing tie up, the company said in a BSE filing.
As part of the agreement, four probiotic products will be introduced by Vesale Pharma in the Indian market, it added.
Morepen Laboratories Chairman and MD Sushil Suri said: "We are delighted to bring Vesale products and technology to India. The range and technology gels very well with our focus on probiotics."
Probiotics are live bacteria, intended to colonise in the human intestine in large numbers, Morepen Laboratories said.
"This agreement we signed with Morepen Laboratories today is perfectly in line with the global strategy and international development of Vesale Pharma. The need for our patented products in the probiotic segment is huge," Vesale Pharma Executive Chairman and CEO Jehan Lienart said.
Vesale brings in patented, easy to use, effective probiotics for people of all ages from infants to geriatrics, he added.
Shares of Morepen Laboratories today closed 10.39 per cent higher at Rs 19.65 per scrip on BSE.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)